IDH1 and acute myeloid leukemia: Hotspot mutations in IDH1 and IDH2 have subsequently been shown to occur in at least 13 types of cancer, including 70% of malignant gliomas, 30% of AML and 5–25% of cholangiocarcinomas [5,9,10,11,15,16,17,18,19].